Amgen scraps experimental weight loss pill, moves forward with injection
Publishing timestamp: 2024-05-02 18:59:23
Summary
Amgen is scrapping its experimental weight loss pill and focusing on its injectable drug called MariTide. The company is pleased with the results so far and is planning late-stage trials for the treatment. Amgen's revenue and earnings for the first quarter exceeded Wall Street's expectations, partly due to products from Horizon Therapeutics. The company slightly narrowed its full-year guidance as well.
Sentiment: MIXED
Tickers: AMGN, NOVO.B-DK, LLY, NVO,
Keywords: novo nordisk a/s, business news, biotechnology, health care industry, earnings, amgen inc, business, pharmaceuticals, biotech and pharmaceuticals, breaking news, eli lilly and co,